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42 molecules which were sold in each country for the period. The countries were 
organised into the WHO regions. In total, around 1,000,000 unique national, product 
brands were accessed for the analysis. Results: Pharmaceutical price indices vary 
substantially between regions. The Asian regions recorded the lowest prices. The 
indices were as follows: South-East Asian Region D 0.21; South-East Asian Region 
B 0.31; European Region B 0.37 Western Pacific Region A; 0.44 European Region A 
0.45; African Region E 0.46; European Region C 0.49; Western Pacific Region B 0.51; 
Eastern Mediterranean Region D; 0.54; Region of the Americas D 0.87; Region of the 
Americas B 0.90; Eastern Mediterranean Region B 1.11. ConClusions: This is the 
largest exercise ever undertaken in comparing international pharmaceutical prices. 
It also employs a more robust method than previous studies. The analysis shows 
Asian region pharmaceutical prices are the lowest in the world.
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objeCtives: Review existing literature to understand the prevalent external price 
referencing (EPR) systems and to audit for directionality of the current mechanisms 
against the components defined in WHO/HAI (World Health Organization/Health 
Action International) project on EPR. Methods: English publications between 
October 2000 and March 2013 investigating EPR systems were identified through 
EBM Reviews – Cochrane Database of Systematic Reviews, NHS Economic Evaluation 
Database; Embase; and MEDLINE searches. Publications on EPR systems were ana-
lyzed in three relevant groups. Qualitative analysis was done to audit the direction-
ality. Results: 101 out of 598 articles were found to be relevant and were placed and 
allocated into three relevant focus groups - 43 general, 44 individual country, and 14 
disease specific reference pricing articles. Regional distribution of publications was 
as follows: 49 RE (Region Europe), 12 Americas, and 15 Asia-Africa-Oceania. Number 
of publications over years was ranging from 3 to 10 with a significant peak in 2011 
at 21.52 articles were found to have directionality against the components defined 
in WHO/HAI project, and the use of several approaches for setting the price was 
commonly discussed. Use of EPR was discussed for both patented and generic drugs. 
Publications showed directionality towards use of several approaches for EPR and 
were directing the use of EPR for both patented and generic drugs. With regards to 
type of price level used, ex-manufacturer price was the dominant option. The for-
mula to derive the target price was directing towards average price. ConClusions: 
There is a growing trend towards increase in number of publications on EPR with 
lead from RE. A number of discussions around the components raised on WHO/HAI 
Project indicate that it is a useful tool to lay out options for ERP. Growing number 
of publications will provide more robust evidence for commonly used options of 
each component.
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objeCtives: In 2003, China introduced a heavily subsidized voluntary health insur-
ance program, the New Rural Cooperative Medical Scheme (NRCMS). This paper 
evaluates the effectiveness of the NRCMS by assessing its impact on health care 
utilization and out-of-pocket health expenditure. Methods: We employ propensity 
score matching (PSM) with single difference and double difference based on data 
from China Health and Nutrition Survey (CHNS) from 1991 to 2009. To check the 
robustness of our results, we also use a bounding approach to test how strongly an 
invariant unobserved variable influences the selection process. For the out-of-pocket 
payments (OOP), a two-part model is used to correct for the large number of zero 
values and the skewness of the data. Results: We find no evidence of an increase 
in the utilization of formal medical care and preventive services. There is a large, 
positive effect on the utilization of village clinics, and large, negative effects in 
town hospitals, county hospitals and city hospitals. For the two-part model of out-
of-pocket (OOP) payments, we find a small, positive impact on the probability of 
positive OOP payments and a small, negative impact on the actual level of OOP pay-
ments. All the effects on the incidence of catastrophic medical payments based on 
different thresholds are insignificant. ConClusions: The results indicate that the 
NRCMS did not increase the overall utilization but directs people from high-level to 
low-level medical facilities. The substitution effect among different levels of facili-
ties may be due to more generous reimbursement in low-level facilities. In addi-
tion, there is no reduction on the out-of-pocket medical payments or the incidence 
of catastrophic health payments. Therefore, the impact of NRCMS on increasing 
utilization and reducing financial risk is found to be limited. The lack of effective-
ness may be attributed to a relatively low premium and shallow benefit coverage.
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objeCtives: To examine the time between regulatory approval and launch/pricing 
and reimbursement (P&R) approval in the EU5 and US. Methods: New molecular 
entities, formulations and combinations approved by the EMA between January 
2009 and December 2013 were included in the analysis. FDA approval dates were 
retrieved and launch dates were gathered as follows: USA: Date wholesale acquisi-
tion cost was effective; UK/Germany: Product availability/introduction; France: P&R 
decision (Agrément collectivités/date published in Journal Officiel); Italy: First P&R 
Decree publication on Official Gazette; Spain: Date of commercialization; and Time 
comparison for general medicines vs. orphan and oncology indications was made 
including shifts over time. Results: Time from approval to launch in the US aver-
plantation purpose. Almost all Category 2A new drugs fulfilled the unmet medical 
needs for infection control, tocolytic therapy in preterm labor, or new mechanism for 
cardiovascular disease. ConClusions: Category 2B new drugs with less financial 
impact to NHI system seem easier to reach listing and reimbursement goal in the 
2-stage assessments. Reasonable budget impact and cost-effectiveness analysis are 
as important as robust comparative effectiveness data for PBRS appraisals. There is 
a need for long-term observation and further analysis.
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objeCtives: The purpose of this study was to identify the main value drivers behind 
the innovation category designations (1, 2A, 2B) assigned during the Taiwanese 
reimbursement process. Methods: All products assessed for reimbursement 
from January 2012 to March 2014 by the National Health Insurance Administration 
(NHIA) were considered in this analysis. The details of the assessments have been 
extracted from the NHIA meeting minutes and Center for Drug Evaluation (CDE) 
reports. Results: Category 1 designations are given to drugs that show “substantial 
clinical improvement”, Category 2A designations to drugs that exhibit “moderate 
improvement”, and Category 2B designations to drugs that provide similar clinical 
value to comparators. Since 2012,94 of 113 products received positive decisions 
from the NHIA. 19 received Category 2A (26%), 51 received Category 2B (71%), while 
2 received Category 1 (3%). Most Category 2B drugs were considered as alternative 
therapeutic options with similar efficacy (94%) to an existing product; others were 
considered to provide better clinical value but a larger budget impact or higher 
price (6%). Most Category 2A drugs were considered to provide additional efficacy, 
safety, or convenience over the comparator (53%). Of the 2 Category 1 products, 
plerixafor was rewarded for its curative potential in hematologic malignancies, as 
well as its potential reduction of hospitalisation costs; azacitidine was rewarded 
for being a first-in-class therapy for Myelodysplastic Syndrome. 22 of 94 products 
did not receive any category, as they were indication expansions. 17 of 113 assessed 
products received negative decisions due to their significant budget impact (59%) 
or lack of clinical benefit (41%). 2 out of 113 decisions are pending. ConClusions: 
Both clinical and economic considerations heavily drive the assessment outcomes 
in Taiwan. In order to achieve a positive assessment outcome in Taiwan, a product 
needs to provide a combination of favourable clinical and economic data.
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objeCtives: Pharmaceuticals can be marketed when regulatory approval has been 
obtained. However other barriers may need to be cleared before patients can gain 
access to subsidised medicines. In the Asia-Pacific region these subsidised systems 
are often government programmes and range from national tax funded schemes 
(Australian Pharmaceutical Benefits Schedule) through to coverage of a specific 
population (Thailand Social Security Scheme for office workers). Navigating these 
systems can be as simple as submitting a pricing application or as complex as a 
full scale societal health technology assessments. The aim of this study is to com-
pare the processes and timings between regulatory approval and subsidised access 
to medicines across the Asia-Pacific region. Methods: Reimbursement guide-
lines from seven different jurisdictions in the Asia-Pacific region were reviewed. 
Differences in processes and time from regulatory approval to subsidised access 
were captured between Australia, China, Japan, Korea, New Zealand, Taiwan and 
Thailand. Results: Only Australia and Thailand allows evaluation of reimburse-
ment in parallel with regulatory evaluation. Parallel processing has been discussed 
in Korea and Taiwan but has not been implemented. The time between regulatory 
approval and subsidised access differs across jurisdictions. In general additional 
processes such as health economic evaluation, pricing negotiation, budget approval 
and administration prolong time to subsidised access well beyond 6 months post 
regulatory approval. Japan is unique as a reimbursement price should be published 
within 60 days after regulatory approval. ConClusions: While most jurisdictions 
in the Asia-Pacific region differ in terms of regulatory and access approval pro-
cesses all but one of the jurisdictions included in this study require a regulatory 
approval letter before reimbursement can be sought. Parallel processing can shorten 
time for patients to access new medicines however other factors such as health 
economic evaluation, pricing negotiation, budget approval and administration are 
also important.
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objeCtives: The study aimed to determine the differences between Asian and 
Global Pharmaceutical prices Methods: The indices were developed using the 
Fisher Elteto, Koves, Szulc (EKS) method. The EKS method is widely used by the 
Organisation for Economic Co-operation and Development (OECD) but has not 
yet been applied to pharmaceutical prices. IMS MIDAS data was used to estimate 
prices and sales volumes. In order to construct the indices, the products needed 
to be defined as like. The definition of like in this study was based on molecules 
which are deemed to deliver equivalent health outcomes. The price indices were 
developed for countries in World Health Organisation (WHO) regions. The analysis 
compares prices across 56 countries over the period from 2005 to 2011 and included 
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determined that the payment amount will be segmented calculated. Besides, com-
mercial companies are responsible to provide insurance. Thus the article sum-
marizes and compares the financing level, deductible and cap lines. Results: 18 
provinces determined the financing level: 11 provinces were from 10 CNY to 60 
CNY per capita annually; the rest equaled 5% to 10% of BMI premium. 22 provinces 
determined deductible: 15 provinces calculated deductible based on urban per 
capita disposable income (or rural per capita net income). 7 provinces determined 
cap line: 4 provinces were from 200 000 CNY to 400 000 CNY and the rest were no 
cap. ConClusions: 1. In all related provinces, the financing level is relatively low, 
while segmented calculation and the cap line lead to high payment. The main chal-
lenge is how to balance the income and expenditure of the insurance. 2. Since the 
central government did not define what critical illness insurance can reimburse, 
some provincial governments strictly control the range. In some other provincial 
governments, like Anhui, the range of the insurance is too wide. However, consid-
ering the insurer is commercial companies, the gaming between companies and 
governments will continue.
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objeCtives: China is the third largest pharmaceutical market in the world. The 
aim of this study was to describe Chinese reimbursement process, assess current 
policies and provide the authors’view of Europeans difficulties to understand the 
Chinese market access. Methods: A review was done using the latest-released 
official documents published by January 2014, to collect information regarding 
Chinese health care reimbursement pathways with the perspective of market 
access. Information was analysed based on authors’expertise, summarising the 
general pathway, and comparing with European routine. Results: Three stake-
holders participate in Chinese market access process: Ministry of Health (MoH) 
(supporting introduction of new health care technologies), National Development 
and Reform Commission (referencing prices based on technical information), and 
Bureau of Human Resources and Social Security (representing budget holders; focus-
ing on cost containment). Differences between Chinese process and European rou-
tine result in European hardly understanding Chinese market access process: 1> in 
China, key opinion leaders introduce the dossier whereas in Europe, companies 
introduce the dossier. 2> in China, completely new health care technologies need 
real life pilot studies (RLPS) pre-requisitely to address the feasibility and impact of 
introduction, whereas in Europe, RLPS studies are requested after a granted market 
access. 3> in China, reimbursements start from regional level as pilot in 3 regions 
before becoming national whereas in Europe they start from national before regional 
contact. 4> in China, the three stakeholders negotiate internally reimbursements, 
prices and access conditions, whereas in Europe, companies negotiate with pay-
ers. 5> Chinese MoH has an envelope for direct funding of health care technologies 
through procurement, whereas no comparable envelope held by similar stakehold-
ers in Europe. ConClusions: Chinese market access is difficult for European to 
understand because of fundamental differences in the paradigm sustaining pricing 
and reimbursement (P&R). Clarifying the rational for the differences in paradigm is 
a prerequisite for European understanding of the P&R in China.
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objeCtives: The objective of this study was to develop a patient centred model 
which can be used by clinicians for each patient. Methods: Two hypothetical, but 
realistic, treatments were selected to demonstrate the value of this model, a “mod-
ern atypical drug” and a “typical drug”. The “modern atypical drug” is more expen-
sive, results in faster return to work, less days in hospital and fewer repeat visits 
than the “typical drug”. The computer based model provides default differences on 
all of these variables, however, the end user can over write these to allow the cost 
off-sets to be individualised to each patient they are treating. Results: While the 
“modern atypical drug” is more expensive on a per day basis ($4.00 vs $0.30), days 
of treatment can be shorter, hospital stay and doctor visits reduced and days off 
work lower, making it a less expensive treatment option overall. In the base case, 
the medication cost of the “modern atypical drug” was $108 more expensive over 
the year of treatment ($4 per day x 30 days versus $0.30 per day x 40 days). Shorter 
length of stay (3 versus 10 days at $50 per day) resulted in $350 in savings. Modest 
savings were gained from fewer doctor visits. Substantial savings would be expected 
from fewer days off work (14 versus 45 days off work at $100 per day) with around 
$3,100 saved. Overall savings were $3,432. This model could be adjusted to reflect the 
expected outcome for each patient. ConClusions: This is exercise demonstrates a 
novel model design which allows doctors to assess individual patients to determine 
whether or not they should be considered for more expensive treatments. It is well 
suited to health care environments in the region.
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objeCtives: Risk sharing agreements (RSA) are sometimes used to offset the risk 
associated with any uncertainties which may surround a drug at the time of launch. 
They can offer payers and manufactures the flexibility to manage some of the per-
ceived risks associated with, but not limited to, high therapy costs, discretionary 
use within an unapproved patient population, or lack of data at the time of product 
assessment. Given the frequent implementation of RSAs in Australia, the aim of 
aged 39 days (17 days for oncology and 14 days for orphan drugs). Across the EU5, 
Germany was fastest while Italy was slowest (16 vs. 66 weeks). Other factors con-
sidered included: UK reimbursement decisions by SMC and NICE often lengthened 
time to access; Germany: Time to market has increased by ~8 weeks since the 2011 
introduction of AMNOG; Italy and France have special license programs which can 
shorten time to market for products addressing unique needs or populations; and 
In Spain commercialization of orphan and oncology drugs takes longer than general 
medications. ConClusions: Average time to market in the US vs. EU5 countries 
is considerably different. In the EU5, the German and UK launch on average were 
within 4 to 6 months of authorization; Italy was greater than a year. Launch times 
for orphan and oncology drugs also differ based on priorities set within health sys-
tems. Differences in country and product type have led to different market access 
timelines and regulatory changes will only increase these disparities.
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objeCtives: To describe policies of drug cost sharing in health insurance schemes 
and how the authors have assessed the effects where available. Methods: A sys-
tematic review was conducted in 2009 and updated in 2013. Results: Totally 28 
studies were included. 1) Some insurance schemes introduced a new drug cost 
sharing program, the increase rates of total number of prescriptions were smaller 
compared with the non cost-sharing group; At the same time, prescription drug cost 
sharing also decreased use of essential drugs or adherence to medications which 
induced adverse effects on vulnerable population such as the poor, the elderly and 
patients with chronic diseases. Average prescription cost increase rate was lower 
in the cost sharing group than the non cost-sharing group. 2) For Different Tiers of 
Prescription Copayment System, there were some positive effects showing that the 
consumption of generic drugs increased in both single-tired and three-tiered groups, 
especially higher proportion in the three-tiered system. Higher levels of prescrip-
tion drug cost sharing actually decrease inappropriate drug use with a relatively 
inelastic price elasticity of demand. For the patients with chronic diseases such as 
heart failure or diabetes, lower adherence of medication followed by higher copay-
ment would increase risk of hospitalization. Different levels of copayment could 
control moral hazard of the patients with decreased rates of switching to a relatively 
more expensive drug and an increased rate of switching to drugs of equal or lesser 
cost. 3) Increasing cost sharing level was followed by decreasing the utilization of 
prescription drugs and increasing in out of pocket especially for the vulnerable 
population. ConClusions: To increase or decrease the level of cost sharing could 
change the beneficiaries’ behavior, the vulnerable population were more sensitive 
than the general. Different levels of cost sharing method seem as one of the suc-
cessful tools to control moral hazard.
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objeCtives: The objective of this study was to identify key value drivers to achieve 
pricing premiums through the similar efficacy comparator pricing method for inno-
vative products in Japan. Methods: We analysed all products that were priced by 
the Central Social Insurance Medical Council (Chuikyo) using the similar efficacy 
comparator pricing method (I) from January 2010 to March 2014. Where relevant, the 
pricing premium and premium criteria met within each category were analysed in 
detail. Results: Of 102 products assessed, 36 products (35%) were granted pricing 
premiums, which ranged from 5-50%. The most common premium category 
was utility (69%), followed by paediatric use (19%) and marketability (17%). Four 
products fell into two categories and were granted both pricing premiums. Of the 
seven orphan drugs assessed, six gained a 10% marketability (I) premium, while 
one achieved marketability (II) with only a 5% premium, as the orphan indication 
was not its main indication. Paediatric-use premiums ranged from 5-10%, with 
higher premiums dependent on unmet need and availability of similar therapies. 
5-15% utility (II) premiums were achieved by products with improved MOA, efficacy, 
safety or therapeutic method. Only two products, fingolimod and telaprevir, were 
designated as utility (I) innovations, which qualified them for pricing premiums of 
35-60%. Fingolimod was the first oral therapy approved to treat relapsing forms of 
multiple sclerosis. Its novel MOA, improved administration and efficacy, as well as an 
orphan indication, secured fingolimod a 50% pricing premium. Similarly, telaprevir 
was also valued by Chuikyo for its novel MOA and significant clinical improvement 
over the standard of care, resulting in a 40% pricing premium. ConClusions: 
Clinical benefit and unmet need are the main value drivers for premium pricing 
in Japan. To achieve > 20% pricing premium, a product needs to meet at least two 
utility premium criteria to be categorized to utility (I).
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objeCtives: China has a complex system to provide basic medical insurance (BMI) 
for over 95% population. However 35% of the total medical expense is out-of-pocket. 
To relieve people’s burden, China implemented critical illness insurance from 2012. 
Critical illness insurance is based on BMI and aims to provide further protection for 
urban and rural unemployed residents. The article aims to summarize the plans 
of critical illness insurance from 24 provinces, to conclude the developments and 
prospects. Methods: The 24 plans were published from October 2012 to December 
2013. The participants of the insurance are urban and (or) rural residents. All plans 
